ESOPHAGEAL CANCER

This study tests a new drug, TQB6411, in people with esophageal cancer that has come back or spread, and who have already tried standard treatments. The goal is to find a safe dose and see if it can shrink tumors or slow the disease. About 105 adults aged 18-75 will take part.

This study tests a drug called zanidatamab in about 200 adults with advanced HER2-positive cancers (like breast, stomach, lung, or ovarian cancer) that have worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how long that effect last…

This early-stage trial tests a new drug (CA-4948) combined with standard chemotherapy and immunotherapy for people with untreated stomach or esophageal cancer that cannot be removed by surgery. The study includes two groups: one for HER2-negative cancer and one for HER2-positive …

This early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another c…

This study looks at two treatment options for people with a type of esophageal cancer that has shrunk after initial chemo-immunotherapy. Half will get standard surgery to remove the tumor, and the other half will get a combination of radiation and chemotherapy instead. The goal i…

This study tests two new drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has worsened after initial treatment. About 210 participants will receive either an experimental antibody-drug conjugate plus standard chemotherapy, o…

This study tests a combination of three treatments—bemosubaiabimab (an immunotherapy), anlotinib (a targeted therapy), and standard chemoradiation—in people with esophageal cancer that has spread to a few other spots (oligometastatic). The goal is to see if this mix can shrink tu…

This early-stage study tests a new treatment called CEA-targeted CAR-T cells for people with advanced solid tumors (such as lung, stomach, colon, rectal, esophageal, or pancreatic cancer) that have not responded to standard therapies. The treatment uses a patient's own immune cel…

This early-phase study tests a new drug called BL-M07D1 in adults with advanced HER2-positive solid tumors (including breast, lung, stomach, and ovarian cancers) that have not responded to at least two prior treatments. The main goals are to check the drug's safety, find the best…

This study looks at people with esophageal or stomach cancer that has spread to only a few spots in the body. After 4 months of standard chemotherapy, some will get local treatment (surgery or radiation) right away, while others will have 4 more months of chemo first. The goal is…

This study aims to find the best treatment before surgery for people with esophageal or stomach cancer. It compares chemotherapy, chemoradiation, targeted therapy, and immunotherapy. The goal is to improve survival and reduce side effects. About 2000 adults with stage I to IVa ca…

This study looks at whether tracking tumor DNA in the blood (ctDNA) can help doctors decide the best treatment for people with advanced esophageal cancer. About 30 participants will receive a combination of immunotherapy and chemotherapy, followed by radiation and chemo. The goal…

This early-stage study tests a new medicine, PF-08046033, in adults with advanced lung, esophageal, or skin cancer that has spread or can't be removed. The main goal is to check safety and find the right dose. Participants receive the drug in cycles and are closely watched for si…

This early-phase study tests a new drug called BL-M17D1 in about 20 people with advanced HER2-positive or low-HER2 cancers of the digestive tract (esophagus, stomach, pancreas, colon) and other solid tumors. The main goals are to check safety, find the best dose, and see if the d…

This study looks at how well the drug T-DXd works for people with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. About 100 adults in the US will be followed to see if their tumors shrink or stop growing. The goal is to u…

This early-stage study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells and boost the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatments.…

This study tests three experimental treatments for people with advanced esophageal, stomach, or colorectal cancers that have spread. The goal is to see if these drug combinations can shrink tumors and how safe they are. About 376 adults aged 18 to 75 will participate. The treatme…

This study tests an experimental drug called MT-4561 in people with advanced solid tumors (like lung, breast, or pancreatic cancer) who have tried at least one prior therapy. The main goals are to find a safe dose and check for early signs of tumor shrinkage. About 27 adults will…

This study tests a new drug, sonesitatug vedotin, combined with chemotherapy (capecitabine) and possibly another drug (rilvegostomig) for people with advanced stomach, gastroesophageal junction, or esophageal cancer that has a specific marker (CLDN18.2) and is HER2-negative. Abou…

This study tests whether adding two targeted drugs (pembrolizumab and trastuzumab) to standard chemotherapy can improve outcomes for people with HER2+ cancer of the esophagus or stomach before surgery. About 49 adults with resectable tumors will receive the combination, then surg…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that have stopped responding to standard treatments. The goal is to find a safe dose and see if it can shrink…

This early-phase study tests TJ101, an experimental antibody-drug conjugate, in 200 adults with advanced solid tumors (lung, prostate, esophageal, and others) who have no standard options left. The main goals are to find a safe dose and check for early signs of tumor shrinkage. P…

This early-phase trial tests a new drug called MDX2001 in about 285 adults with advanced solid tumors (cancers that have spread). The main goals are to check the drug's safety and find the right dose. Researchers will also see if it shrinks tumors. This is not a cure, but it may …

This phase 3 trial tests whether adding two drugs—toripalimab (an immunotherapy) and capecitabine (a chemotherapy pill)—after standard chemoradiation can prevent esophageal cancer from coming back. About 242 adults with advanced esophageal cancer that hasn't progressed after init…

This early-stage study tests a new drug, enzelkitug, given alone or with standard immunotherapy drugs, in people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and find the right dose. About 450 adults with cancers like lung, …

This early-phase study tests an experimental drug called PF-08046876 in adults with advanced solid tumors (bladder, lung, head/neck, esophagus, or pancreatic cancer) that have not responded to standard treatments. The drug is an antibody-drug conjugate designed to stick to cancer…

This study looks at whether giving artificial nutrition through a feeding tube (jejunostomy) before surgery can lower the chance of complications after the operation. It includes 670 malnourished adults with esophageal or stomach cancer who are receiving pre-surgery treatment. Th…

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to standard chemotherapy and radiation before surgery helps people with a certain type of esophageal cancer live longer. About 422 adults with stage T1-4aN1-3M0 or T3-4aN0M0 squamous cell esophageal cancer wil…

This study tests a new approach for people with advanced esophageal cancer that cannot be removed by surgery. It combines a cancer-killing virus with chemotherapy and an immunotherapy drug. The goal is to shrink tumors enough to allow surgery and improve long-term outcomes. About…

This study tests whether adding new investigational drugs to standard chemotherapy and immunotherapy (pembrolizumab) can safely shrink tumors in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. About 160 adults whose …

This study tests an experimental oral drug called NEO212 in adults with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it can slow tumor growth. About 134 participants will receive NEO212 a…

This study tests a new drug called HLX43 for people with advanced esophageal cancer that has come back or spread after standard first treatment. The drug is designed to find and attack cancer cells while limiting harm to healthy cells. About 102 participants will receive the drug…

This study tests a new treatment called EBNK-001, which uses donor immune cells (natural killer cells) to fight advanced solid tumors. About 83 adults with cancers like lung, breast, or colorectal cancer that have not responded to standard treatments will receive these cells alon…

This study looks at whether supervised exercise can improve recovery in people who have had surgery for esophageal or gastric cancer. About 171 participants will be assigned to high-intensity interval training, low-intensity continuous training, or usual care for 8 weeks. The mai…

This study tests whether adding a precise internal radiation treatment (brachytherapy) after standard external radiation, chemotherapy, and the immunotherapy drug nivolumab can help prevent esophageal cancer from returning. About 60 adults with advanced esophageal squamous cell c…

This study tests whether adding low-dose or standard radiation to the usual combination of immunotherapy and chemotherapy can better control metastatic esophageal squamous cell carcinoma. About 100 adults with stage IVB cancer who have not had prior treatment will participate. Th…

This early-phase study tests a new drug called BL-B01D1 in people with advanced lung cancer and other solid tumors that have spread or cannot be removed. The main goals are to check safety, find the best dose, and see if the drug shrinks tumors. About 470 adults will take part.

This early-stage trial tests a new combination treatment for people with advanced HER2-positive solid tumors (like breast, lung, or stomach cancer). Participants receive an injection of a special virus directly into one tumor to activate the immune system, followed by an infusion…

This early-stage study tests a new drug called SH009 in about 150 people with advanced solid tumors (like liver, lung, or breast cancer) that have not responded to standard treatments. The main goal is to see if the drug is safe and can shrink tumors. Researchers will also measur…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The drug targets a protein called HER3 found on some cancer cells. About 740 adults with various cancers like lung, breast, or melanoma w…

This study tests whether adding the immunotherapy drug iparomlimab after standard chemoradiation can help older adults (70+) with inoperable esophageal cancer live longer without their cancer growing. About 52 participants will receive chemoradiation followed by one year of iparo…

This study is testing a new treatment that uses a radioactive substance to target and destroy cancer cells in people with advanced solid tumors (like pancreatic, stomach, or ovarian cancer) that have not responded to standard treatments. The therapy works by attaching to a protei…

This study tests whether a combination of the immunotherapy drug camrelizumab and chemotherapy can shrink esophageal tumors enough to avoid surgery and keep the esophagus intact. About 283 adults with resectable esophageal squamous cell cancer will receive the treatment before an…

This study tests whether a special vacuum device placed inside the body can prevent dangerous leaks where the esophagus is reconnected to the stomach after cancer surgery. About 44 adults having minimally invasive esophageal cancer surgery will receive this preventive treatment. …

This study tests whether giving two different chemotherapy and radiation regimens one after the other (total neoadjuvant therapy) works better than standard treatment for patients with esophageal cancer that has spread to nearby lymph nodes. About 216 adults with resectable cance…

This study tests whether adding targeted radiation and an immunotherapy drug (durvalumab) to a short course of chemotherapy and radiation can help control advanced esophageal cancer and relieve trouble swallowing. About 54 adults with cancer that has spread to a few other spots o…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study tests a new drug called LY4052031 in people with advanced or spreading solid tumors, including bladder, breast, lung, and other cancers. The goal is to see if the drug is safe and works against these cancers. About 420 participants will take part, and the study will la…

This study is for people with advanced esophageal cancer that cannot be removed by surgery. Researchers want to see if starting with a short course of immunotherapy plus chemotherapy can help guide the next steps. Based on how the tumor responds, patients will get either the same…

This study tests a new type of PET scan that looks for a protein called CLDN18.2 on cancer cells. It includes 56 adults with stomach, pancreatic, bile duct, or esophageal cancer, plus healthy volunteers. The goal is to see if this scan can accurately find tumors and help doctors …

This study tests a special dye and imaging system that makes cancer cells glow, helping surgeons see and remove tumors more completely during surgery for colorectal, pancreatic, esophageal, and gastric cancers. About 66 adults scheduled for surgery will receive the dye beforehand…

This study tests an FDA-approved dye called CYTALUX (pafolacianine) that attaches to cancer cells and glows under a special camera during surgery. About 50 adults with certain gastrointestinal or gynecologic cancers will get the dye before their operation. The goal is to see if t…

This study tests a new type of PET scan called [¹⁸F]FAPI-74 to see if it can more accurately detect whether stomach or esophageal cancer has spread to other parts of the body. About 200 adults with these cancers will receive one dose of the imaging agent and then be scanned. The …

This study is testing a simple, non-invasive method to detect early signs of Barrett's esophagus, esophageal cancer, and stomach cancer. Participants swallow a capsule attached to a string that collects cells from the esophagus and stomach. Researchers then analyze the DNA in tho…

This study aims to see if certain chemicals in a person's breath and blood can help detect early-stage gastro-esophageal cancer. Researchers will compare samples from people with cancer, those with Barrett's esophagus (a pre-cancer condition), and healthy volunteers. Participants…

This study is testing whether a special PET scan called 18F-AraG can find esophageal tumors and predict how well they respond to chemoradiation. About 60 adults with untreated, locally advanced esophageal cancer will receive the scan before and during treatment. The goal is to im…

This study is testing a blood test that looks for DNA signals from 20 different cancers, including lung, breast, and colon cancer. Researchers will see if the test can find cancer early and tell which type it is. In people with lung cancer, the test will also check for any cancer…

This study tests whether a dye called CYTALUX™, given before surgery, can help surgeons see cancer tissue in real time using a special camera. It includes 15 adults with stomach, esophagus, or appendix cancer who are already scheduled for surgery. The goal is to see if this techn…

This study looks at whether a short exercise program before esophageal cancer surgery is practical and helpful for patients. About 20 people preparing for surgery will take part. The goal is to see if patients stick with the program and if it improves their recovery and treatment…

This study tests whether a program of exercise and nutrition supplements before esophageal cancer surgery is practical and helpful for patients. Twenty adults scheduled for surgery will either receive the pre-surgery program or standard care. Researchers will measure how many pat…

This study tests whether adding personalized integrative care—like naturopathic support, a Mediterranean diet, and physical activity—before and after surgery can improve quality of life and reduce complications for people with lung, stomach, or esophageal cancer. About 20 adults …

This study tests whether a special airway device (COMBO Endoscopy Oropharyngeal Airway) combined with high-flow oxygen can prevent low oxygen levels in severely obese patients during sedated endoscopy. About 410 adults with a BMI of 35 or higher will be randomly assigned to recei…

This pilot study tests if brodalumab, a drug approved for autoimmune diseases, can safely reduce severe side effects caused by cancer immunotherapy. About 11 adults with various solid tumors who have immune-related side effects will receive brodalumab. The goal is to see if it lo…

This study tests a new device called the COMBO Endoscopy Oropharyngeal Airway in 580 obese patients (BMI 28 or higher) undergoing sedated gastrointestinal endoscopy. The device combines oxygen support, airway management, and monitoring to reduce the risk of hypoxia (low oxygen le…

This study is for people with advanced esophageal cancer that cannot be cured. It tests whether adding two chemotherapy drugs (carboplatin and paclitaxel) to standard radiation therapy can better relieve trouble swallowing and improve quality of life. About 50 adults with swallow…

This study tests whether a high-flow nasal cannula (a device that delivers warm, moist oxygen) can prevent dangerously low oxygen levels during sedated gastrointestinal endoscopy in people at high risk for obstructive sleep apnea. Researchers will enroll 600 adults with a STOP-Ba…

This study is testing a structured rehabilitation program for 100 people in southern Sweden who have esophageal or stomach cancer and are scheduled for surgery. The goal is to see if the program can improve quality of life and reduce cancer-related symptoms. Participants will be …

This study tests whether a tailored palliative care plan can help people with advanced esophageal cancer live longer and feel better. About 624 adults whose cancer has spread or returned and who are receiving immunotherapy will be randomly assigned to either precision or standard…

This study is testing whether using a breathing machine (CPAP or BiPAP) during radiation therapy can reduce tumor movement in people with advanced lung cancer, esophageal cancer, or lymphoma. The goal is to see if this approach makes radiation more accurate and reduces side effec…

This study is testing whether an artificial intelligence (AI) model can predict how well esophageal cancer will respond to treatment and the patient's long-term outlook. Researchers will analyze medical images, genetic data, and other health information from 1,500 participants. T…

This study collects tissue, blood, urine, and stool samples from 5,000 people undergoing colonoscopy or endoscopy, including those with cancer, polyps, or inflammatory bowel disease, as well as healthy volunteers. The goal is to find new biomarkers that could lead to better scree…

This study aims to understand why some cancers come back after surgery by detecting tumor cells and DNA in blood, urine, and bone marrow. Researchers will collect samples from 620 adults with various solid cancers (like lung, colon, or pancreatic cancer) and track their health ov…

This study is collecting medical history, blood, and tissue samples from 7,000 people with esophageal disorders like GERD or Barrett's esophagus. Researchers hope to find genetic or protein markers that signal a higher risk of developing esophageal cancer. The goal is to enable e…

This study looks back at the medical records of 4000 people who had surgery for esophageal cancer. The goal is to learn how the edges of removed tissue (called margins) relate to how long patients live. No new treatments are given; instead, researchers hope to find patterns that …

This study is collecting survey responses from 1,000 people who have had or will have surgery for esophageal cancer or other upper digestive problems. The goal is to create a standard way to measure symptoms and recovery after treatment. The information will help doctors better m…

This study tracks how often esophageal cancer spreads to a specific lymph node near the windpipe. Researchers will follow about 1,850 patients to identify risk factors and survival outcomes. The goal is to better understand this type of spread, not to test a new treatment.

This study reviews past medical records to see if people with esophageal cancer have better survival rates at hospitals that perform many surgeries compared to those that do fewer. Researchers will compare death rates between high-volume and low-volume hospitals. The goal is to u…

This study collects sputum and tissue samples from 700 people with precancerous lung changes or certain cancers (lung, head and neck, esophageal). Researchers look for genetic markers that might help detect cancer earlier. The goal is to build a tissue bank for future research, n…

This study collects tissue and blood samples from people with stomach or esophageal cancer, as well as those at high inherited risk, to learn how genes and proteins contribute to these cancers. The goal is to better understand the disease, not to test a new treatment. About 100 p…

This study looks at whether giving the chemotherapy drug paclitaxel over a longer time (2-3 hours) to cancer patients with low muscle mass can make the drug level in their blood similar to patients with normal muscle mass who get the standard 1-hour infusion. About 22 women with …

This study looks at whether adding a geriatrician to the care team can improve outcomes for people aged 70 and older with gastrointestinal cancers like stomach, colon, or pancreatic cancer. Researchers will test if an online fitness questionnaire is easy to use and if geriatric c…

This study is testing whether a blood test that looks for tiny bits of tumor DNA (ctDNA) can find cancer early after treatment. Researchers will follow about 100 people with different solid tumors, plus healthy volunteers, to see if the test helps predict when cancer comes back. …

This study looks at how a specific gene, ALDH2, which helps break down alcohol, might affect how long people with esophageal cancer live. Researchers will follow 700 patients for up to 150 months to see if certain gene variations are linked to better or worse survival. The goal i…

This study is creating a huge collection of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand cancer causes, improve early detection, and develop person…

This study is for people with certain advanced cancers (like lung, head and neck, or esophageal cancer) who are already receiving immunotherapy. Researchers want to see if adding radiation therapy improves outcomes and, more importantly, if changes in immune cells in the blood ca…

This study looks at whether changes in DNA markers in the blood can show how well esophageal cancer treatment is working. Researchers will compare these markers to standard scans and tumor tests. The goal is to find a simpler, less invasive way to monitor the disease and guide tr…

This study looks at how often esophageal cancer spreads to lymph nodes located behind the windpipe. Researchers will track 1,100 patients to find out which factors increase the risk of this spread. The goal is to help doctors decide on the best treatment approach.

This study looks at tissue samples from 30 people with stomach or esophageal cancer that spread to the brain. Researchers compare the genetic features of the original tumor and the brain tumor to see if they differ. The goal is to understand how the cancer changes when it spreads…

This study follows 3500 people who had surgery for esophageal cancer to compare recovery and quality of life between minimally invasive and open surgery. Participants fill out questionnaires about their physical and mental well-being for up to 3 years after surgery. The goal is t…

This study is a large registry that will follow 8,000 cancer patients who receive radiation therapy guided by an MR-Linac, a machine that combines an MRI scanner with a radiation beam. The goal is to see if this technology helps people live longer, controls tumors better, and imp…

This study collects blood, urine, and bone marrow samples from 320 people with solid cancers (like lung, colon, or pancreatic cancer) and from those undergoing lung cancer screening. The goal is to detect tiny bits of tumor cells and DNA in these fluids to learn how cancer spread…

This study uses a 20-25 minute survey to find out which features of diagnostic tests for gastro-esophageal cancer matter most to patients and the general public. Researchers aim to understand preferences and regional differences to improve screening decisions. Over 2,200 adults a…

This study aims to create a tool that predicts whether a person's stomach will still have food or liquid in it during a sedated endoscopy, which can cause serious complications like choking. Researchers will observe 5000 adults undergoing the procedure, measure stomach contents, …

This study looks at how radiation treatment for esophageal cancer affects the body's ability to respond to the pneumonia vaccine. Researchers will measure antibody levels in 80 patients before and after vaccination. The goal is to understand if low white blood cell counts caused …

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…